SHENZHEN, China, Jan. XNUMX / PRNewswire /) - - BGI is aware of reports from Reuters about the company's non-invasive prenatal test (NIPT) - NIFTY (Non-Invasive Fetal TrisomY).
The BGI's NIPT tests are used worldwide to detect genetic diseases during pregnancy. These tests provide doctors with the science behind them to help millions of pregnant women, resulting in better health outcomes and, in some cases, saved lives.
Research conducted by BGI in collaboration with some of the world's leading academic and scientific institutions has resulted in significant medical breakthroughs that will benefit the world for many decades to come.
As a leading company in the fields of life sciences and genetic engineering, BGI is committed to improving health care worldwide. That is and always has been the company's mission. Claims that BGI is motivated by anything other than promoting health outcomes are both deeply disappointing and factually incorrect.
These are the facts:
- BGI has never and has never been asked to share data from its NIFTY test with Chinese authorities for national security or national defense security purposes.
- Contrary to the Reuters report, DNA data collected from prenatal tests on women outside of China is not stored in China's gene bank. All NIPT data collected abroad are stored in the BGI laboratory in Hong Kong and destroyed after five years, as prescribed by the General Data Protection Regulation (GDPR).
- Contrary to Reuters claims, the NIPT test was developed by BGI alone - not in partnership with China's military.
- At no point in the test or research process does BGI have access to identifiable personal data or the possibility of comparing this data with personal records.
- Wherever BGI conducts research, the company strictly adheres to local laws, guidelines and protocols while adhering to internationally recognized ethical standards.
- The data protection standards that BGI uses for its research meet strict national and international requirements, including the GDPR in the European Union.
- BGI works with many academic and research organizations not only in China but also with many of the world's most prestigious institutions in the US, UK and Europe. These collaborations have resulted in significant advances in medical science that are improving the health of populations around the world.
BGI is a global organization driven by innovation, focused on precision medical research, with a desire to reduce the harm of serious diseases to people worldwide.
Since its inception in 1999, BGI has had a consistent track record of applying the strictest ethical standards and protecting privacy and security. We established the Institute of Review Board of Bioethics and Biosafety (BGI-IRB) to recognize, advocate, and guide the life science research and technological applications of the BGI.
We pride ourselves on the achievements of our scientists and we are committed to continuing to work with our partners around the world to drive new advances in life science and healthcare.
Inquiries & contact: